CClinicalTrials.gg
RecruitingNCT07579871SnSRehabSUpdated Sep 24, 2026

Sleep and Stroke Rehabilitation Study

An observational study in Stroke, Sleep Apnea Syndrome (OSAS) and Insomnia, sponsored by Malin Eleonora av Kák Gustafsson, MD, PhD. Recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Malin Eleonora av Kák Gustafsson, MD, PhD · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
226
Ages
18 Years and older
Sex
All
01

Study summary

The study aims to map sleep disorders and their impact on the ability to engage in an active daily life among people who have had a stroke, with particular focus on how sleep apnea can be identified.

The study has the following objectives:

  1. To examine the occurrence of sleep apnea, insomnia, excessive daytime sleepiness, and restless legs syndrome/periodic limb movements in patients with ischemic stroke three months after onset.
  2. To investigate associations between these sleep disorders and physical and mental health, fatigue, quality of life, cognitive and physical function, and daily physical behavior including physical activity levels.
  3. To identify which clinical factors and patient reported data, including patient reported data from commercial wearable health technology, predict a diagnosis of sleep apnea.
  4. To examine how sleep disorders affect changes in physical and mental health, fatigue, quality of life, cognitive and physical function, and daily physical behavior including physical activity levels one year after stroke.
Read the detailed description

There is currently a lack of understanding regarding how common sleep disorders are after stroke and how extensive their impact is on physical and psychological conditions. This project will investigate how common sleep disorders are in connection with stroke and how they affect patients with stroke physically and psychologically, as well as their level of activity in everyday life.

The project will also examine how healthcare services could identify who should undergo an assessment for sleep apnea. Today, there are commercial health technology products that alert users to potential breathing problems during the night, but it is unclear whether the information a patient presents to their doctor, based on these commercial health technology products, should be included in the clinical assessment of sleep apnea risk.

The project will consecutively invite individuals with stroke from Skåne and Blekinge, Sweden. Three months after their stroke, participants will complete questionnaires, undergo actigraphy and wear a commercial health technology product in the form of a smartwatch for one week, as well as complete an overnight respiratory recording. Based on this, it will be possible to determine how many participants have a sleep disorder and how it has affected them, as well as which factors make it likely that an individual has sleep apnea.

02

Conditions studied

  • Stroke
  • Sleep Apnea Syndrome (OSAS)
  • Insomnia
  • Excessive Daytime Sleepiness

Keywords

  • actigraphy
  • HSAT
  • Quality of life
  • rehabilitation
  • recovery
  • smartwatch
  • sleep
  • stroke
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with stroke residing in the local referral area of Skåne University Hospital (SUS) or in the local referral area of the Department of Medicine at Blekinge Hospital Karlskrona.

Inclusion criteria

  • Ischemic stroke.
  • First time stroke.

Exclusion criteria

Exclusion Criteria:

  • Short expected survival.
  • Unable to carry HSAT equipment (e.g., gel nails; the patient is wearing other medical devices; motor or cognitive impairment without the possibility of assistance from healthcare staff or relatives).
  • Reduced understanding of the project due to insufficient Swedish, which cannot be bridged with an interpreter.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
226 participants (estimated)
Target follow-up
9 Months
Patient registry
Yes

Groups and cohorts

  • Patients with ischemic stroke

    Patients with first-time ischemic stroke in Skåne and Blekinge, Sweden.

05

What researchers measure

Primary outcomes

  1. Occurrence of sleep apnea

    Percent of participants with sleep apnea as assessed by Home Sleep Apnea Testing.

    Time frame: Three months post-stroke.

  2. Occurrence of insomnia

    Percent of participants with insomnia.

    Time frame: Three months post-stroke.

  3. MoCA

    MoCA (Montreal Cognitive Assessment) is a cognitive screening tool scored 0-30, where higher scores indicate better cognitive function; a score of 26 or above is considered normal, with an optional +1 point for individuals with ≤12 years of education.

    Time frame: Twelve months post-stroke.

  4. MoCA

    MoCA (Montreal Cognitive Assessment) is a cognitive screening tool scored 0-30, where higher scores indicate better cognitive function; a score of 26 or above is considered normal, with an optional +1 point for individuals with ≤12 years of education.

    Time frame: Three months post-stroke.

  5. Occurrence of excessive daytime sleepiness

    Percent of participants with excessive daytime sleepiness.

    Time frame: Three months post-stroke.

  6. Physical movement behavior

    Amount of time spent in different postures and activities during 24 hours.

    Time frame: One week of continuous accelerometer monitoring three months post-stroke.

  7. Physical movement behavior

    Amount of time spent in different postures and activities during 24 hours.

    Time frame: One week of continuous accelerometer monitoring twelve months post-stroke.

  8. HADS

    HADS (Hospital Anxiety and Depression Scale) includes two subscales (anxiety and depression) scored 0-21 each. 0 indicates no symptoms, and 21 indicates the most severe symptoms.

    Time frame: Three months post-stroke.

  9. HADS

    HADS (Hospital Anxiety and Depression Scale) includes two subscales (anxiety and depression) scored 0-21 each. 0 indicates no symptoms, and 21 indicates the most severe symptoms.

    Time frame: Twelve months post-stroke.

  10. FAS

    FAS (Fatigue Assessment Scale) is scored 10-50. 10 indicates no fatigue, and 50 indicates the most severe fatigue.

    Time frame: Three months post-stroke.

  11. FAS

    FAS (Fatigue Assessment Scale) is scored 10-50. 10 indicates no fatigue, and 50 indicates the most severe fatigue.

    Time frame: Twelve months post-stroke.

  12. EQ-5D

    EQ-5D produces an index score ranging from \<0 to 1. 1 indicates full health, and lower values indicate worse health (with values below 0 representing health states considered worse than death).

    Time frame: Three months post-stroke.

  13. EQ-5D

    EQ-5D produces an index score ranging from \<0 to 1. 1 indicates full health, and lower values indicate worse health (with values below 0 representing health states considered worse than death).

    Time frame: Twelve months post-stroke.

  14. Level of breathing difficulties

    Patient-reported breathing difficulties based on information they obtained from their commercial digital health smartwatch.

    Time frame: Three months post-stroke.

Secondary outcomes

  1. Hba1c

    HbA1c (Hemoglobin A1c) mmol/mol. Represents the average amount of blood sugar attached to hemoglobin over the past two to three months

    Time frame: Baseline.

  2. Cholesterol

    Serum cholesterol in mmol/L

    Time frame: Baseline.

  3. Creatinine

    Serum creatinine in µmol/L.

    Time frame: Basline.

06

Study locations

1 of 1 sites recruiting
  • Skånes Universitetssjukhus, SUS
    Lund, Skåne County, Sweden
    Recruiting
07

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the results reported in the published article. No directly identifiable information will be shared, and all data will be processed in accordance with the EU General Data Protection Regulation (GDPR).

Supporting information: Study protocol, Sap, Icf, Analytic code

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07579871
Lead sponsor
Malin Eleonora av Kák Gustafsson, MD, PhD
Collaborators
Region Skane, Lund University
Responsible party
Malin Eleonora av Kák Gustafsson, MD, PhD (Postdoc, Region Skane) — Sponsor-investigator
First posted
May 12, 2026
Start date
Mar 18, 2026
Primary completion
Oct 30, 2028 (estimated)
Completion
Oct 30, 2028 (estimated)
Last update
Sep 24, 2026

Study contacts

Malin E. a. K. Gustafsson, M.D., Ph.D.
Contact
malin_e.gustafsson@med.lu.se
0046451-29 60 00

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion